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Medial calcification refers to mineral deposition in the middle layer of arteries.
This mineralization is common in chronic kidney disease patients and causes an increased
chance of cardiovascular complications. Calcitriol, the active form of vitamin D, is often
administered to these patients to treat an associated condition, secondary
hyperparathyroidism. Unfortunately, calcitriol treatment may promote vascular
calcification due to increasing serum calcium and phosphate. We examined the effects of
calcitriol supplementation on vascular smooth muscle cell (VSMC) calcification, through
atomic absorption, scanning electron microscopy, and western blot analysis.
Additionally, we examined the effects of the combinations of calcitriol, fibroblast growth
factor 23 (FGF-23), and klotho. We determined that calcitriol supplementation alone
increased calcification but was not associated with a transition towards an osteoblast-like
phenotype. On the other hand, the combination of calcitriol and FGF-23 caused a
decrease in calcification, but this decrease was attenuated with the further addition of
klotho.
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CHAPTER I
INTRODUCTION
Vascular Calcification
Vascular calcification is the pathological deposition of calcium-phosphate bone
mineral in arteries. Two forms of vascular calcification exist depending on the location of
the mineral deposition within the artery: intimal calcification and medial calcification
(also known as Mönckeberg’s arteriosclerosis).
As seen in Figure 1.1, the intima layer of arteries refers to the inner layer
consisting of a layer of endothelial cells that lines the lumen, or inside, of the blood
vessel. Intimal calcification occurs with atherosclerosis, which is the thickening of an
artery wall caused by endothelial dysfunction followed by the invasion of white blood
cells and the migration of smooth muscle cells. These molecular events lead to the
accumulation of cells (living and dead), cellular debris, and lipids, together referred to as
plaque (1). Plaque can expand such that it partially or completely occludes the lumen,
which can eventually lead to problems if the downstream supply of blood becomes
insufficient. Often times, the plaque can also rupture, revealing material that can induce a
thrombus, or blood clot, formation in the artery. This thrombus can occlude the artery
directly or break off forming a down-stream embolism. Occlusions can become lifethreatening when they occur in the coronary arteries or arteries in the brain by causing a
myocardial infarction (heart attack) or stroke, respectively. Intimal calcification refers to
1

the calcification of the plaque; however, research has been inconclusive as to the
consequences of intimal calcification in atherosclerosis. Autopsies have revealed a
relationship between calcification and plaque burden (2). As for rupturing, some studies
suggest that the calcification of the plaque causes locations for high local stresses that can
increase the chance for rupture (3). On the other hand, heavily calcified plaque is
believed to be less likely to develop a thrombus (4), and finite element analysis suggests
calcification may serve to stabilize the plaque, similar to the fibrous cap, by lowering the
maximum stresses throughout the structure (5).

Figure 1.1

Schematic of Artery Structure

Arteries are composed of three distinct layers: tunica intima (inner), tunica media
(middle), and tunica externa (outer). From Wikipedia.org
Also seen in Figure 1.1, the tunica media refers to the middle layer of arteries
consisting of vascular smooth muscle cells (VSMCs) and elastic fibers composed of the
extracellular matrix protein elastin. In medial calcification, mineral deposition occurs
2

along these elastic fibers. Medial calcification is often associated with chronic kidney
disease (CKD), diabetes, and ageing. While there are not traditional symptoms due to this
mineral deposition, calcification of elastic fibers causes increased arterial stiffness
(measured by pulse wave velocity), which can result in damage to organs, such as the
heart and kidneys. As such, research has shown that medial calcification is correlated
with an increased risk of total and cardiovascular mortality in type 2 diabetes patients (6)
and CKD patients on hemodialysis (7).
Intimal and medial calcification are not entirely exclusive and can be present
simultaneously, especially in CKD patients with atherosclerosis. Also, research has
suggested that the pathomechanism between intimal and medial calcification may share
many similarities (8). However, they remain distinctly different both morphologically and
with respect to clinical implications. For these reasons, this project with be solely focused
on medial calcification in CKD patients.
Mechanism of Medial Calcification
Initially, medial calcification was considered a passive process, in which the
calcium and phosphate in the serum precipitated out and formed minerals along the
extracellular matrix. However, it is now widely accepted to be an active cellular-process
similar to bone formation. Many factors are believed to be involved in the initiation of
this process, such as inflammatory molecules, certain growth factors, and oxidative
stresses; however, for CDK patients, the most important factor is high concentrations of
calcium and phosphate. Numerous studies have shown that phosphate and calcium are
able to increase calcification in a concentration-dependent and synergistic manner (9-13).
Some of the key events that are believed to be required for the initiation of vascular
3

calcification include: 1) the trans-differentiation of VSMCs into osteoblast-like cells, 2)
the release of matrix vesicles and apoptotic bodies, 3) the loss of calcification inhibitors,
and 4) the degradation of the extracellular matrix.
The resident VSMCs in the medial layer are able to transdifferentiate into
osteoblast-like cells due to their shared mesenchymal stem cell lineage. Observed both in
vitro and in vivo, this phenotypic transition is characterized by the loss of smooth muscle
lineage markers, such as smooth muscle α-actin (αSMA), smooth muscle myosin heavy
chain (SM-MHC) and SM22α, and the increased expression of bone genes and proteins,
such as core binding factor α1 (Cbfa1/runx2), osteopontin (OPN), osteocalcin (OCN),
and alkaline phosphatase (ALP) (13-16). The produced bone proteins, especially ALP,
promotes the deposition of the calcium-phosphate mineral. Intracellular phosphate is
directly involved in the phenotypic transition, as the addition of phosphate alone is
capable of inducing this phenotypic transition in VSMC cultures (13). Calcium is also
involved in the phenotypic change, but it is believed to be an indirect action, as the
increase in calcification caused by calcium addition does not involve the upregulation of
ALP (17). It is worth noting that VSMCs grown on calcified elastin in vitro also undergo
this phenotypic switch (16); thus, it is possible for calcium’s role in the phenotypic
switch to be through increasing the mineral deposition through the other main roles,
which in turn, further promotes the differentiation towards osteoblast-like cells.
Two different membrane bound bodies, matrix vesicles (MV) and apoptotic
bodies (AB), play large roles in the initiation of mineral formation. MVs are small (20200 nm) extracellular vesicles formed from budding off of the outer plasma membrane of
viable cells. They contain large amount of calcium and phosphate, providing a suitable
4

microenvironment for the nucleation of hydroxyapatite formation. This occurs naturally
in the calcification of bone, cartilage, and dentin (18), but research has shown that they
are also involved in pathological conditions, specifically medial calcification (12, 19-21).
TEM images of calcified bovine VSMCs grown in the presence of β-glycerophosphate
and ascorbic acid revealed membrane-bound MVs associated with calcification (20).
They were also found in vivo when observing the calcified aortas of matrix gla protein
(MGP) deficient mice, which undergo extensive medial calcification (19). The addition
of calcium and/or phosphate to VSMC cultures cause increase MV release (12, 21),
presumably in an effort to avoid toxicity caused by high intracellular calcium and
phosphate. In addition, while MVs are produced naturally, those produced from the
addition of phosphate have an increased ability to calcify, associated with increased ALP
activity and increased calcium uptake through annexin expression (22). ABs are larger
vesicles formed from the fragmentation of cells undergoing apoptosis. In vitro studies
show that high concentrations of phosphate and calcium increase apoptosis (12) and
apoptosis increases calcification of human VSMCs (23, 24). The ABs released from
apoptosis can also serve as nucleating sites for mineralization similar to MVs (12, 23).
For both vesicles, high extracellular phosphate and calcium increases the tendency of
these vesicles to mineralize (12).
In non-pathological conditions, natural inhibitors to calcification are present in
various tissues, as well as matrix vesicles produced by VSMCs, in order to prevent
ectopic calcification despite relatively high serum levels of phosphate and calcium. One
such endogenous inhibitor is matrix Gla protein (MGP), a vitamin-K dependent protein
expressed in VSMCs. While MGP binds directly to hydroxyapatite (25), the method of
5

inhibition is not entirely clear (26). Selective knock-down of MGP causes severe medial
calcification (19) and low amounts of activated MGP are found in diabetes patients (27).
Another inhibitor that is produced by VSMCs is pyrophosphate, which directly inhibits
calcification by binding to calcium phosphate, preventing mineral nucleation and further
growth. ALP promotes calcification through hydrolyzing pyrophosphate (28). There are
also circulating inhibitors that are not directly produced by VSMCs, such as fetuin-A.
Produced predominately in the liver (29), it also binds to calcium phosphate, preventing
mineral nucleation, and can be taken up by VSMCs to prevent calcification (30).
Expression of these inhibitors are decreased through the phenotypic switch of the VSMCs
or through the increased secretion of MVs, allowing the mineralization process to take
place.
The role of calcium and phosphate in extracellular matrix degradation
(specifically elastin degradation in medial calcification) is not clear; however, research
has provided a lot of evidence for involvement of elastin degradation in medial
calcification. It was first discovered that matrix metalloproteinase-2 and -9 (MMP-2/-9),
the proteins responsible for breaking down elastin, are upregulated in areas of
calcification in vivo (31-33) and abolishment of this MMP activity prevents the
calcification process (34-36). Later, research was able to show that the products of elastin
degradation actually accelerate the mineralization process and phenotypic switch of the
VSMCs (37). The most recent research has actually shown that the degradation of elastin
precedes the deposition of hydroxyapatite mineral and that the mineralization only occurs
along the degraded elastin fragments (32). These results, as well as belief that degraded
elastin has an increased affinity of calcium (38), have lead researchers to suggest that
6

extracellular matrix degradation creates sites for the initial nucleation and subsequent
growth of the calcium-phosphate mineral in medial calcification.
These events that are involved in medial calcification are tightly connected and
are all believed to be affected by high extracellular concentration of calcium and
phosphate. Due to this relationship, proper mineral metabolism is important to preventing
vascular calcification, and that requires the actions of the molecules vitamin D,
parathyroid hormone (PTH), fibroblast growth factor 23 (FGF-23), and klotho.
Vitamin D
Vitamin D and its metabolites are secosteroid hormones that play a key role in
calcium homeostasis as well as other important roles in hormone production, immune
system regulation, and differentiation of cells. Although the name implies that it is a
vitamin, it is technically considered to be hormone as it is predominately produced in the
body and doesn’t necessarily have to be obtained through dietary intake if enough is
produced endogenously. Secosteroids are similar to steroids in both structure and
function. The difference in structure is the broken carbon-carbon bond in the B ring of the
typical four-ring structure of steroids. Functionally, they are similar in that they both act
on their specific nuclear receptor. Two forms of vitamin D exist: vitamin D3, or
cholecalciferol, and vitamin D2, or ergocalciferol. Vitamin D3 is produced in the human
body, specifically in the skin, in response to ultraviolet (UV) radiation. Vitamin D2 is
produced in plants and fungi also in response to UV radiation and can be obtained
through dietary intake. The two forms are structurally and functionally different;
however, the extent of the functional differences are still highly debated. Research has
shown that a single dose of vitamin D2 produces less of the circulating metabolite than a
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single dose of vitamin D3 (39, 40); however daily doses of vitamin D2 and D3 maintain
similar levels of the circulating metabolite (41). Due the potential functional differences
as well as the fact that the majority of vitamin D is obtained endogenously, this study will
be focused primarily on vitamin D3 and its metabolites.
As alluded to previously, the metabolites of vitamin D3 are extremely important
because vitamin D3, as produced by the skin, is inactive and requires multiple subsequent
enzymatic reactions to be fully active. The structure of vitamin D3 and its metabolites as
well as the sequence of events leading from synthesis to activation can be seen in Figure
1.2. First, 7-dehydrocholesterol, present in the epidermis, is converted into pre-vitamin
D3 with UV light exposure. Pre-vitamin D3 will then isomerize into vitamin D3 in a
temperature-dependent reaction (42). In order to prevent vitamin D3 toxicity from
prolonged UV exposure, pre-vitamin D3 can be converted to tachysterol and biologically
inactive lumisterol, which can be reversed when pre-vitamin D3 levels drop (43). To
become active, vitamin D3 is converted into 25-hydroxyvitamin D3 [25(OH)D3], or
calcidiol, through enzymatic reaction by 25-hydroxylase (CYP2R1) in the liver. This
reaction is highly dependent on the amount of vitamin D3 present and is the major form
found circulating in the blood, which is why serum levels of 25(OH)D3 are usually
measured to determine if a patient has sufficient amount of vitamin D (44). To become
fully active, 25(OH)D3 must be converted to 1,25-dihydroxyvitamin D3 [1,25(OH)2D3], or
calcitriol, through enzymatic reaction by 1α-hydroxylase (CYP27B1) in the proximal
renal tubule of the kidneys. Other tissues contain the CYP27B1 enzyme; however, they
are believed to function to provide local concentration of calcitriol for paracrine or
autocrine functions (45). It is also believed that this local production does not affect the
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circulating concentration produced from the kidneys. Finally, calcitriol is carried to the
target tissue where it exerts effects and deactivated by breaking down it to the watersoluble calcitroic acid by the enzyme 1,25-dihydroxyvitamin D3 24-hydroxylase
(CYP24A1).

Figure 1.2

Synthesis and Activation of Vitamin D

Synthesis of vitamin D3 begins in the skin from UV radiation and goes through
subsequent activation in the liver and kidneys. From (46)
Vitamin D, specifically calcitriol, elicits its response similar to traditional
steroids, by acting on specific nuclear receptors. The receptor responsible for vitamin D’s
response is aptly named vitamin D receptor (VDR). The VDR forms a heterodimer that
interacts with specific DNA sequences, causing either expression or repression of
transcription. As seen in Table 1.1, there are at least 36 tissues that express the VDR.
While many of these tissues are involved in calcium homeostasis and bone remodeling
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(which will be discussed in more detail in a later section), the other tissues are involved
in vitamin D’s many nontraditional roles, including hormone production, regulation of
immune system, and differentiation of cells. Research has shown that, while the
mechanism isn’t well understood, calcitriol stimulates insulin secretion (47) and suggests
that vitamin D deficiency increases the risk for type 2 diabetes (48). As for the immune
system regulation, calcitriol has a complex role, as it has an inhibitory effect on the
proliferation of many cells of the adaptive immune system, such as B cell precursors (49)
and T helper-1 cells (50), but is actually able to increase expression of the antimicrobial
peptide cathelicidin in the innate immune system (51). Finally, calcitriol is involved in
the proliferation and differentiation of cells, such as keratinocytes in the epidermis (52),
and may have an inhibitory role on certain cancers (53).
Table 1.1
Adipose
Adrenal glands
Bone
Bone marrow
Brain
Breast
Cancer cells
Cartilage
Colon

From (54)

Tissues that Express VDR
Eggshell gland
Epididymis
Hair follicle
Intestine
Kidney
Liver (fetal)
Lung
Lymphocytes (B and T)
Muscle, cardiac

Muscle, embryonic
Muscle, smooth
Osteoblast
Ovary
Pancreas β cell
Parathyroid glands
Parotid
Pituitary glands
Placenta

Prostate
Retina
Skin
Stomach
Testis
Thymus
Thyroid
Uterus
Yolk sac (bird)

PTH, FGF-23, and Klotho
Regulation of the serum calcium and phosphorus levels is done through strict
cooperation between the bone, kidneys, and parathyroid glands. Besides vitamin D (in the
form of calcitriol), there are three other key molecules involved in this process:
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parathyroid hormone (PTH), fibroblast growth factor 23 (FGF-23), and its coreceptor
klotho.
PTH is an 84 amino acid long polypeptide hormone produced and secreted by the
parathyroid glands in response to serum calcium (and serum phosphate to a lesser
degree). The mature polypeptide is stored in secretory vesicles for release. As a
regulatory mechanism, PTH undergoes intracellular degradation also in response to
extracellular calcium levels, which is sensed through a G-protein-linked calcium receptor
(55). When calcium levels are low (hypocalcemia), PTH secretion increases and
intracellular degradation is reduced. When calcium levels are high (hypercalcemia), PTH
secretion decreases and intracellular degradation is increased. Once secreted, PTH acts to
restore serum calcium levels (a process that will be discussed in more detail in the next
section). PTH is quickly cleared (T1/2 = 4 minutes) through the kidneys and liver (56).
FGF-23 is a protein produced from osteocytes in bone that respond to serum
phosphate levels. FGF-23 belongs to the fibroblast growth factor (FGF) superfamily;
however, it differs from the majority of FGF ligands in that it does not contain a heparansulfate (HS) binding domain. HS is found as a proteoglycan bound at cell surfaces and in
the extracellular matrix. Because FGF-23 lacks a HS binding domain, it is able to avoid
matrix binding and able to move into circulation to exert its endocrine function, instead
of the paracrine and/or autocrine functions of traditional FGFs (57). Only two other FGFs
lack the HS binding domain, FGF-19 and -21, and together they are referred to as
endocrine FGFs. FGFs bind to one of four FGF receptors (FGFR1-FGFR4), which
consist of 3 extracellular domains, a single-pass transmembrane domain, and a
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cytoplasmic tyrosine kinase domain (58). Because HS binding is required for FGF-FGFR
binding (59), FGF-23 requires a coreceptor, klotho (60).
Klotho is considered an “anti-aging” protein that is expressed predominately in
the distal convoluted tubules in the kidney. It is a type I single-pass transmembrane
protein but can also be found in a soluble, secreted form from the proteolytic cleavage, or
“shedding”, of the transmembrane protein (61). As previously mentioned, the
transmembrane klotho acts as a coreceptor for FGF-23 for phosphate regulation. The
secreted klotho can be found circulating in the blood, urine, and cerebrospinal fluid (62).
While not well understood, its effects are believed to be independent of FGF-23, and may
play a role in regulation of calcium and potassium ion channel activity (63, 64). Klotho
became known as the “anti-aging” protein because mice with defective klotho gene
expression experience phenotypes that resemble accelerated aging, displaying symptoms
such as shortened lifespan, infertility, arteriosclerosis, skin atrophy, osteoporosis, and
emphysema (65). In addition, overexpression of klotho in mice caused increased life-span
compared to wild-type mice (66). The effects of klotho can be explained in part by its
role as coreceptor for FGF-23, as FGF-23 knockdown causes a similar phenotypes (67)
and excess phosphate itself can causes stresses that may lead to accelerated aging.
Mechanism of Bone/Kidney-Endocrine Axis
The regulation of calcium and phosphate requires the interaction between the
bone, kidneys, and pituitary glands, through the actions of PTH, calcitriol, FGF-23, and
klotho. A schematic of this process can be seen in Figure 1.3.

12

Figure 1.3

Bone/Kidney-Endocrine Axis

Serum calcium and phosphate are regulated by complex interactions between the bone,
kidneys, and parathyroid glands. From (68)
When serum calcium is low, the parathyroid glands increases secretion (and
decreases intracellular degradation) of PTH. PTH acts to increase calcium production
through three separate functions: 1) PTH acts directly on osteoblasts in bone to increase
expression of receptor activator of NF-κB ligand (RANKL), causing increased osteoclast
activation and subsequent bone resorption and release of calcium and phosphate into the
extracellular fluid; 2) PTH acts on the kidneys to increase the reabsorption of calcium by
Ca2+-ATPase and a Na+-Ca2+; and 3) PTH acts on the proximal renal tubules in the
kidneys to increase CYP27B1 expression, causing increased production of calcitriol (55).
Calcitriol acts to increase the active absorption of calcium and phosphate in the intestinal
13

lumen of the gut. As calcium levels normalize, the parathyroid glands sense the decrease
in serum calcium and PTH secretion decreases, ceasing bone resorption. In addition to
serum calcium, calcitriol acts directly on the parathyroid glands to decrease PTH
secretion (69, 70).
As for phosphate regulation, an increase in serum phosphate (71), along with
direct action by calcitriol (72, 73), causes an increase in FGF-23 production from the
osteocytes in the bone. FGF-23 with the coreceptor klotho decreases phosphate
reabsorption in the proximal tubules by reducing the expression of sodium-phosphate
cotransporter type-2a (NaPi-2A) and type 2c (NaPi-2C) (74). In addition, FGF-23 lowers
serum calcitriol levels through down regulation of the CYP271B1 gene and upregulation
of the CYP24 gene in the kidneys, simultaneously reducing the amount of calcitriol being
produced and increasing the hydrolysis of the calcitriol already in circulation (75). FGF23 further decreases the serum levels of calcitriol by directly acting on the pituitary
glands to reduce PTH secretion (76), preventing PTH from creating more active vitamin
D. This action prevents the further absorption of phosphate in the intestines and allows
for net phosphate wasting.
Chronic Kidney Disease
CKD is characterized by the gradual loss of kidney function and can be grouped
into 5 different states, with stage 4 and 5 known as end stage renal disease (ESRD). As
the kidneys stop functioning, the body’s method of maintaining proper calcium and
phosphate levels also stops functioning.
In advanced CKD patients, when serum calcium levels drop, the calcium receptor
in the parathyroid glands respond normally by producing PTH. Also as normal, PTH acts
14

on the osteoblasts in bone to increase RANKL production. However, because of the
impaired kidney function, PTH cannot increase activation of 25(OH)D to calcitriol.
Because there is insufficient calcitriol, calcium cannot be absorbed in the gut and the
body is forced to increase PTH production further to obtain the calcium from bone. As
the PTH production continues, patients can develop secondary hyperparathyroidism,
which is the excess production of PTH due to low serum calcium and can result in the
weakening of bones and possibly calciphylaxis. As for phosphate, the impaired kidney
functions causes a decrease in phosphate excretion through urine and results in high
serum phosphate (77). Klotho expression is reduced in the proximal tubules (78) and, as
such, FGF-23 cannot act to reduce serum phosphate levels. It is believed that as serum
phosphate continues to rise, the body responds by increasing FGF-23 secretion. Research
has shown that serum FGF-23 levels are found increasing as CKD progresses, although it
did not respond to dietary phosphate intake (79). The high FGF-23 levels also contribute
to the secondary hyperparathyroidism problem by decreasing the activation and
increasing the hydrolysis of calcitriol (75).
Research has shown that CKD patients have a high prevalence of cardiovascular
disease and cardiovascular related mortality (80, 81), and medial calcification often
occurs in these patients (7). As previously described, extracellular phosphate and calcium
play large roles in the mechanism of medial calcification. With the high serum phosphate
levels in CKD patients, the high prevalence of medial calcification is understandable.
While serum calcium levels are typically low during CKD, treatments options for
secondary hyperparathyroidism and hyperphosphatemia, such as calcium
supplementation, calcium-containing phosphate binders, and calcitriol treatment, can
15

elevate serum calcium levels (82), also promoting medial calcification and cardiovascular
complications. While research has shown that calcitriol treatment increased the survival
rate of CKD patients (83), the evidence supporting calcium’s role in medial calcification
has led researchers to study calcitriol’s role in the medial calcification in CKD.
Vitamin D and Vascular Calcification
In order to determine if calcitriol treatment promotes VSMC calcification, many
in vitro and in vivo studies have been conducted. However, the results have often been
contradictory, and, as such, researchers cannot definitively conclude whether calcitriol
treatment increases or decreases medial calcification and whether it acts systemically or
locally to produce its effects.
The first study to reveal detrimental effects of calcitriol supplementation on
VSMC, published in 1998 by Jono et al., showed that calcitriol treatment on bovine
VSMCs in vitro concentration dependently increased calcification and ALP activity in
the presence of high phosphate in the form of β-glycerophosphate (84). Mizobuchi et al.
were later able to show that calcitriol treatment in 5/6 nephrectomized rats resulted in
increased serum calcium and phosphate levels, aortic calcification, and runx2 mRNA
expression (85). Another study showed that calcitriol supplementation (at dosages of 100
nM and higher) increased calcification in vitro rat VSMC grown with βglycerosphosphate. In addition, they noted that calcitriol treatment caused an increase in
RANKL expression, but that the addition of RANKL by itself was not sufficient to
increase calcification. They also examined it in vivo using 5/6 nephrectomized rats and
reached the same conclusions as Mizobuchi et al, except that serum phosphate levels
were not upregulated (86). Han et al recently published an article that not only showed
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that calcitriol supplementation increased calcification in mouse VSMC cultures in high
phosphate conditions, but that it also increased calcification in non-calcifying conditions.
In vivo, they treated VDR knockout mice with calcitriol and noted no medial calcification
occurred (87).
On the other hand, other studies have shown that calcitriol supplementation
decreases calcification. In vivo experiments using low density lipid receptor-deficient
mice with renal ablation and fed a high-fat diet showed decreased calcification with
calcitriol treatment. It must be noted that in this model of CKD, only atherosclerotic
plaque and intimal calcification was found (88). In vitro, calcitriol supplementation on
human VSMCs in the presence of high phosphate and tumor necrosis factor-α (an
inflammatory cytokine shown to accelerate calcification in high phosphate conditions)
resulted in decreased calcification at a concentration of 100 nM (no effect with smaller
dosages). Calcitriol did not have an effect on calcification causes by high phosphate alone
(89). Because the role of inflammation is not well understood in medial calcification but
highly important in intimal calcification, this study may also not apply to medial
calcification. In 2012, Lau et al contradicted previous in vivo studies when they showed
that calcitriol treatment actually decreased arterial calcification in 5/6 nephrectomized
mice fed a high phosphate diet. They showed this decrease was correlated with an
increase in serum klotho (although kidney expression of transmembrane klotho was not
increased) (90). These in vivo results tended to agree with the in vitro work by Lim et al
who were able to show that calcitriol treatment increased transmembrane klotho
expression in cultured human VSMCs and able to decrease calcification only with the
addition of FGF-23. FGF-23 and calcitriol by themselves did not affect calcification (91).
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Finally, many other studies have revealed mixed results that suggest that calcitriol
acts systemically to increase calcification through serum phosphate and/or calcium, but
do not directly act on VSMCs to produce the effect. Wu-Wong et al found no significant
difference in calcification of human VSMC in vitro between the control and 100 nM
calcitriol treatment at four different concentrations of phosphate (0.9, 1.48, 2.06, and 2.64
mM). However, while they did not test calcitriol in vivo, treatment of 5/6 nephrectomized
rats with an analog of calcitriol (that also didn’t increase in vitro calcification) resulted in
medial calcification (92). Stubbs et al came across interesting results when they observed
FGF-23 null mice with various diets. FGF-23 null mice with a normal diet had
accelerated mortality associated with increased calcification, calcitriol, serum calcium,
and serum phosphate. Interestingly, low-phosphate dietary restriction in the FGF-23 null
mice resulted in no arterial calcification, despite high serum calcitriol, and vitamin Ddeficient diet resulted in increased calcification, despite low serum calcium and calcitriol
(serum phosphate was still elevated) (93). Very similar results were found when klotho
knockout mice were observed. Klotho knockout mice displayed growth retardation,
increased calcification, and increased serum calcium, phosphate, FGF-23, and calcitriol.
With genetic inactivation of the sodium-dependent phosphate transporter (in addition to
the knockout of klotho), serum phosphate levels were normalized and vascular
calcification was abolished, despite the continued high serum calcium and calcitriol (94).
Lastly, Lomashvili et al took an interesting route of observing the differences between
systemic and local reaction to calcitriol treatment by transplanting both VDR deficient
and VDR functioning aortas into mice with renal failure (and functioning VDR
expression). Calcitriol treatment did increase aortic calcification; however, there was no
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difference between the VDR -/- and VDR +/+ allografts nor was there a significant
difference between the allografts and the adjacent aortas (95).
Taken together, these results are highly contradictory. This may be explained, in
part, by the lack of consistency in testing calcitriol, such as different species of animals
and cells, different concentrations of phosphate, and different dosages of calcitriol.
However, more evidence is starting to suggest that calcitriol’s effect on VSMC
calcification may involve the complex interaction with other molecules, such as FGF-23
and klotho, which may also help explain some of the differences found between the in
vitro and in vivo studies.
Specific Aims
With previous studies unable to come to conclusive results on the effects of
calcitriol supplementation on VSMC calcification, we wanted to examine its effects on
our model of in vitro calcification. In addition, we wanted to explore some of the possible
interaction effects between calcitriol, FGF-23, and soluble klotho. This project can be
broken up into 4 aims:


Examine the utilization of calcitriol in media of calcifying and noncalcifying VSMCs



Examine the concentration-dependent effect of calcitriol supplementation
on degree of calcification in calcifying and non-calcifying VSMCs



Examine the effect of 100 nM calcitriol supplementation on calcifying and
non-calcifying VSMCs (protein expression and morphological changes)



Examine the potential interaction effects of calcitriol, FGF-23, and soluble
klotho on VSMC calcification
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CHAPTER II
MATERIALS AND METHODS
Materials
Calcitriol (catalog no. 2551) was obtained from Tocris Biosciences (Bristol,
United Kingdom). Recombinant human klotho (catolog no. 5334-KL-025) and
recombinant human FGF-23 (catolog no. 2604-FG) were obtained from R&D Systems
(Minneapolis, MN).
For western blot analysis, anti-ALP rabbit monoclonal antibodies (catalog no.
Ab108337), anti-αSMA mouse monoclonal antibodies (catalog no. Ab7817), anti-SMMHC mouse monoclonal antibodies (catalog no. Ab683), and anti-klotho rabbit
monoclonal antibodies (catalog no. Ab181373) were obtained from Abcam (Cambridge,
MA). Anti-ERK 1 (catalog no. SC93) and anti-ERK 2 (catalog no. SC154) rabbit
polyclonal antibodies were obtained from Santa Cruz Biotechnology (Dallas, TX).
For gelatin zymography, 10% Ready Gel Zymogram gel (catalog no. 1611167),
10x Zymogram Renaturing buffer (catalog no. 1610765), 10x Zymogram Development
buffer (catalog no. 1610766), Zymogram Sample buffer (catalog no. 1610764), Precision
Plus Protein Standards (catalog no. 1610373), and 10x Tris/Glycine/SDS buffer (catalog
no. 1610772) were all obtained from Bio-Rad (Hercules, CA).
All other materials were obtained from either Fisher Scientific (Waltham, MA) or
Sigma-Aldrich (St. Louis, MO).
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Cell Culture
Human primary aortic VSMCs were purchased from ATCC (catalog no. PCS100-012; Manassas, VA). Cells were grown and maintained using standard growth
media, Dulbecco’s Modified Eagles Medium (DMEM) with 10% fetal bovine serum
(FBS) and 1% penicillin/streptomycin. Cells were incubated at 37oC with 5% CO2, and
media was changed every 2-3 days.
For experiments, to prepare the calcification media, 3 mM inorganic phosphate in
the form of dibasic sodium phosphate was added to the cell culture media. For
experiments involving the addition of calcitriol, 10% charcoal-stripped FBS was used in
place of regular FBS due to FBS containing vitamin D metabolites. Cells were at passage
8 for all experiments.
Calcitriol Utilization: Experimental Design
HVSMCs were seeded in six-well plates and allowed to grow to 80% confluency.
Cells were dived into two groups: one group received standard growth media (Cont); the
other group received calcification media (Calc).
Once reaching ~80% confluency (Day 0), the cells were given their appropriate
media and allowed to grow for 7 or 14 days, with the media being changed every 2-3
days. On day 4 and day 11, for the 7 and 14 day samples respectively, media samples
were taken prior to administration on the cells and stored in the -80o C. On day 7 and day
14, media samples were taken from each sample prior to removal and subsequent
quantification of calcium deposition. The media samples before and after administration
to the cells were examined for calcitriol concentration.
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Determination of Calcitriol Concentration
The change in calcitriol concentration was determined by measuring the calcitriol
concentration in the media before and after administration using a calcitriol competitiveenzyme-linked immunosorbent assay (ELISA) kit, purchased from Elabscience (catalog
no. E-EL-0016; WuHan, P.R.C), following manufacturer’s instructions. Briefly, the wells
in the microtiter plate were precoated with calcitriol. Sample was added to each well and
“competed” with precoated calcitriol for the biotinylated detection antibodies that were
added to each well. After the reaction, each well was washed to remove excess conjugate
and the unbound calcitriol from the samples. Next, avidin, horseradish peroxidase
conjugate was added to each well and incubated. Then, a tetramethylbenzidine substrate
was added to each well. This enzyme-substrate reaction was terminated with the addition
of sulphuric acid and the resulting color change was measured spectrophotometrically at
450 nm, using a µQuant microplate spectrophotometer (Bio-Tek Instruments; Winooski,
VT).
Calcium Deposition Quantification
Media was removed from the cell cultures, and each well was rinse gently with 1x
phosphate buffered saline (PBS) three times in order to remove any residual media and its
associated calcium. Next, the cell layer was decalcified by using 5 mL of 0.6 N HCl for
24 hours. HCl supernatants were collected and prepared for atomic absorption (AA) by
adding 1 mL of 20,000 µg/mL potassium chloride and 1 mL of 0.1 N nitric acid. The cell
layers were then solubilized using 1 mL of 0.1 N NaOH/0.1% sodium dodecyl sulfate
(SDS) solution. Six-well plates were observed using a light microscope to ensure
complete solubilzation before collection and storage in the -80o C freezer.
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Calcium concentration of HCl supernatant was determined with AA. It was
conducted using a Shimadzu AA-7000F (Shimadzu Corp; Kyoto, Japan) and Calcium
Atomax Hollow Cathode Lamp (catalog no. N2025208; PerkinElmer; Waltham, MA)
using a wavelength of 422.7 nM. Standards containing known calcium values were
prepared using calcium reference standard solution purchased from Fisher Scientific
(catalog SC191-500; Waltham, MA).
Calcium content was normalized to intracellular protein content. Protein
concentration of the NaOH/SDS solution was determined using the Pierce bicinchoninic
acid (BCA) assay (catalog #: 23225; Thermo Scientific; Waltham, MA) following
manufacturer’s instructions. Briefly, standards containing known protein values were
prepared using a stock solution of bovine serum albumin. Standards and samples were
then placed in a non-treated 96-well microplate. An alkaline solution containing BCA
and copper (II) sulfate was added to each well and allowed to incubate at 37oC for 30
minutes. The resulting color change was measure spectrophotometrically at 562 nm.
Protein concentration of the samples were determined by comparing the absorbance of
the samples to the absorbance of the protein standards.
Effects of Calcitriol Concentration: Experimental Design
HVSMCs were seeded in six-well plates and allowed to grow to 80% confluency,
using standard growth media. Cells were divided into 8 groups (n=6):


Standard growth media with 1% ethanol, (Vehicle Cont)



Standard growth media with 10 nM calctriol (10 nM Cont)



Standard growth media with 100 nM calcitriol (100 nM Cont)



Standard growth media with 1000 nM calctriol (1000 nM Cont)
23



Calcification media with 1% ethanol (Vehicle Calc)



Calcification media with 10 nM calcitriol (10 nM Calc)



Calcification media with 100 nM calcitriol (100 nM Calc)



Calcification media with 1000 nM calcitriol (1000 nM Calc)

All media was made with 10% charcoal-stripped FBS. Calcitriol was
reconstituted in 100% ethanol and added to the media, such that the final concentration of
ethanol in the media was 1%.
Once reaching ~80% confluency (day 0), cells were given their appropriate media
and allowed to grow for 14 days, with the media being changed every 2-3 days. After 14
days, cells were decalcified and the degree of calcium deposition was quantified as
previously mentioned.
In-Depth Examination of Calcitriol Supplementation: Experimental Design
Due to results from previous experiment, supplementation of 100 nM calcitriol
was chosen for further in-depth examination. HVSMCs were seeded in six-well plates
and allowed to grow to 80% confluency, using standard growth media. Cells were
divided into 4 groups:


Standard growth media with vehicle (Cont)



Standard growth media with 100 nM calcitriol (100 nM Cont)



Calcification media with vehicle (Calc)



Calcification media with 100 nM calcitriol (100 nM Calc)

All media was made with 10% charcoal stripped FBS. Calcitriol was reconstituted
in DMEM with 1.25% ethanol and added to the media, such that the final concentration
of ethanol in the media was 0.005%.
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Once reaching ~80% confluency (day 0), cells were given their appropriate media
and allowed to grow for 7 or 14 days, with the media being changed every 2-3 days.
Separate samples were prepared for AA (n=6), scanning electron microscopy (n=3), and
western blot analysis (n=3). Media was collected from AA samples prior to
decalcification for analysis of MMP-2/-9 expression using gelatin zymography.
Visualization of Calcium Deposition
Visualization of the calcium deposition was done using scanning electron
microscopy (SEM). Prior to seeding cells in the six well plates, Thermanox plastic
coverslips were placed in the wells with the treated side face-up. After receiving the
appropriate media for 7 or 14 days, media was removed and cells were fixed in 1/2
Karnovsky’s fixative in 0.1 M sodium cacodylate buffer for up to two weeks. The
samples were processed for SEM imaging by further fixation using 0.4% osmium
tetroxide followed by serial dehydration, using increasing concentrations of ethanol and
hexamethyldisilazane (HMDS). Next, samples were allowed to air dry overnight and
mounted on stubs using double-sided tape. Lastly, mounted samples were sputtered
coated with 15 nm of platinum using an EMS 1150T ES sputter coater.
Samples were imaged using a Carl Zeiss EVO50VP Variable Pressure Scanning
Electron Microscope. Working distance of 10 mm and excitation voltage of 10 kV was
used.
For quantification of the calcified area, three images (1000x or lower
magnification) were randomly selected from each group. Percent area of the calcium
deposits in relation to the total area of the image was done using ImageJ software.
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Because edges of cells appeared bright in SEM images, they were manually removed
from the analysis.
Examination of Protein Expression
Protein was obtained by placing cells in lysis buffer (10 mM Hepes, 150 mM
NaCl, 1.5 mM MgCl2, 1 mM EDTA, 10 mM Na-pyrophosphate, 10 mM NaF, 0.1 mM
Na-orthovanadate, 1% Na deoxycholate, 1% Triton x 100, and 0.1% SDS), scraped,
sonicated on ice for 5 seconds, and centrifuged at 15000 RPM to remove large cellular
debris. Protein concentration was determined using BCA assay and diluted such that 30
µg of protein was loaded in each well. Samples were loaded into the wells of 10% or 8%
SDS-Page gel and ran at a constant voltage (120 V) for approximately 2 hours or until
tracking blue dye reached the bottom. Once finished, gels were transferred to PDVF
membrane overnight.
Membranes were blocked with 5% non-fat dry milk in 1x TTBS w/ Tween-20
buffer for one hour at room temperature. Primary antibodies were added to 5% milk in 1x
TTBS w/ Tween-20 buffer, solution was placed on membranes, and membranes were
allowed to shake overnight at 4o C. Membranes were rinsed with 1x TTBS w/ Tween-20
buffer. Secondary antibodies were added to 1% milk with 1x TTBS w/ Tween-20 buffer
and placed on membranes for 1-2 hours at room temperature. Enhanced
chemilumniescence (ECL) solution was added to each membrane and allowed to incubate
5 minutes at room temperature. Membranes were developed on film.
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Examination of MMP-2/-9 Expression
Media samples taken prior to decalcification for AA analysis were diluted in order
to normalize to intracellular protein content. One part media was added to two parts
Zymogram Sample Buffer, and 30 µl of the combined solution was added to each well.
Gels were run at constant voltage (125 V) for 90 minutes or until the bromephenol blue
tracking dye reached the bottom of the gel. Once completed, gels were removed from the
casing and incubated in 1x Zymogram Renaturing buffer for 1 hour with gentle agitation.
Gels were then incubated in 1x Zymogram Development buffer for an hour with gentle
agitation, replaced with fresh development buffer, and allowed to incubate over night at
37o C. The following day, gels were stained with 0.25% (w/v) Coomassie blue stain
(made in 40% methanol, 10% acetic acid, and 50% distilled water) for one hour. Finally,
the gels were destained twice, using a solution of 40% methanol, 10% acetic acid, and
50% distilled water and gentle agitation for one hour.
MMP expression was viewed as clear bands on a dark, stained background.
Densitometric analysis of the band intensity was done using ImageJ software. Band
intensities were normalized to the band for the 7 day control group.
Effects of Calcitriol, FGF-23, and Klotho Supplementation: Experimental Design
HVSMCs were seeded in six-well plates and allowed to grow to 80% confluency,
using standard growth media. Samples were divided into 8 groups:


Standard growth media with vehicle (Cont)



Calcification media with vehicle (Calc)



Calcification media with 100 nM calcitriol (Vit D)



Calcification media with 0.4 nM soluble klotho (Klotho)
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Calcification media with 10 ng/mL FGF-23 (FGF)



Calcification media with 100 nM calcitriol and 10 ng/mL FGF-23 (Vit D
+ FGF)



Calcification media with 100 nM calcitriol and 0.4 nM soluble klotho (Vit
D + Klotho),



Calcification media with 10 ng/mL FGF-23 and 0.4 nM soluble klotho
(FGF + Klotho)



Calcification media with 100 nM calcitriol, 10 ng/mL FGF-23, and 0.4 nM
soluble klotho (All)

All media was made with 10% charcoal stripped FBS. Calcitriol was reconstitute
in DMEM with 1.25% ethanol. Klotho was provided in a solution containing 20 mM 2(N-morpholino)ethanesulfonic acid (MES), 0.1 mM ethylenediaminetetraacetic acid
(EDTA), and 50% (v/v) glycerol and was diluted using DMEM. FGF-23 was reconstitute
per manufacturer’s instructions using 1 x PBS with 0.1% BSA and diluted in DMEM.
The final concentration of the vehicle in each media was 0.005% (v/v) ethanol, 2.7 nM
MES, 135 pM EDTA, 0.000007% (v/v) glycerol, 0.005 % (v/v) PBS, and 0.00005%
(w/v) BSA.
Once reaching ~80% confluency (day 0), cells were given their appropriate media
and allowed to grow for 14 days, with the media being changed every 2-3 days. After 14
days, cells were decalcified and the degree of calcium deposition was quantified as
previously mentioned
Statistical Analysis
Error bars on graphs represent standard deviation. When comparing two groups,
student t-test was used (α= 0.05). When comparing multiple groups, one way ANOVA
with Fisher’s Least Significant Difference (LSD) post-hoc analysis was used (α= 0.05).
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CHAPTER III
RESULTS
Calcitriol Utilization by Calcifying and Non-Calcifying VSMCs
Calcitriol concentration of the cell culture media was measure before and after
administration to both control and calcification groups of VSMCs. As seen in Figure 3.1,
the calcitriol concentration of the media from both groups increased after administration
to the cells at both 7 and 14 days. However, the extent of increase was not significantly
different between the two groups at either time point.

Figure 3.1

Change in Calcitriol Concentration of Media from Calcifying and NonCalcifying VSMCs

There was no significant difference between the increase of calcitriol concentration of the
two groups at either 7 or 14 days
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Calcification of the VSMCs receiving the 3 mM inorganic phosphate was verified
through AA. As seen in Figure 3.2, the VSMCs receiving the phosphate supplementation
had a significant increase in calcium content compared to the control group at both 7 and
14 days.

Figure 3.2

Confirmation of Calcification of VSMC with Phosphate Supplementation

* P < 0.05 compared to the control group at the same time point
Effects of Calcitriol Concentrations on VSMC Calcification
To examine any concentration dependent effect of calcitriol, three concentrations
of calcitriol (10, 100, and 1000 nM) were added to VSMCs with and without the
supplementation of 3 mM inorganic phosphate. As seen in Figure 3.3, only 1000 nM
calcitriol was able to cause a significant increase in calcium content in VSMCs in noncalcifying conditions. In calcifying conditions, seen in Figure 3.4, supplementation of
100 nM and 1000 nM calcitriol caused a significant increase in calcium content
compared to the vehicle. There was no significant difference between the 100 and 1000
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nM groups. It is worth noting that while 1000 nM calcitriol supplementation was able to
increase calcification in the control group, the calcium content value of 1000 nM control
group was still approximately 10 times lower than the vehicle calcification group.
Comparisons of the control and calcification groups can be seen in Figure 3.5.

Figure 3.3

Effects of Three Calcitriol Concentrations on Extent of VSMC
Calcification in the Absence of Phosphate Supplementation

* P < 0.05 compared to vehicle
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Figure 3.4

Effects of Three Calcitriol Concentrations on Extent of VSMC
Calcification in the Presence of Phosphate Supplementation

* P < 0.05 compared to vehicle

Figure 3.5

Combined Graph of Effects of Three Calcitriol Concentrations on VSMC
Calcification
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In-Depth Analysis of Calcitriol Supplementation on VSMC Calcification
To further analyze the effects of calcitriol supplementation on VSMC
calcification, one concentration of calcitriol was chosen (100 nM). The increase in
calcification of VSMCs observed in the previous experiment was confirmed using AA
and observed qualitatively using SEM. Protein expression was examined using western
blot analysis (for αSMA, ALP, and Klotho) and gelatin zymography (for MMP-2 and -9).
The calcium content of VSMCs can be seen in Figure 3.6. Surprisingly, at 7 days,
the supplementation of 100 nM caused a significant increase in calcification in noncalcifying conditions, while there was no effect in the calcification groups. On the
contrary, at 14 days, we observed a significant increase in calcium content with the
addition of calcitriol in the calcification groups but not the control groups.

Figure 3.6

Effect of 100 nM Calcitriol Supplementation on VSMC Calcification at 7
and 14 Days

* P < 0.05 compared to the vehicle for the same treatment and time point
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We imaged the effects of calcitriol supplementation on VSMC calcification
through SEM imaging. SEM images (at 1000x magnification) after 7 and 14 days can be
seen in Figure 3.7 and Figure 3.8, respectively. SEM images at other magnifications can
be seen in Figures A.1, A.2, A.3, and A.4. Comparing the images at day 7, there appears
to be more small nodules in the calcification groups compared to the control groups.
Although the AA data showed that there was increase in calcification between the 7 day
control and 7 day 100 nM control groups, there does not appear to be any distinct
morphological differences in the images of these groups. The 14 day images are similar
to the 7 day images in that the calcification groups appear to have more nodule
formations than the control groups. Also, while AA data showed an increase in
calcification with the supplementation of 100 nM calcitriol in the 14 day calcification
group, there did not appear to be any distinct morphological differences between the two
groups. Quantification of the calcified area, as seen in Figure 3.9, did not show any
significant differences in the percent area of calcification with the supplementation of 100
nM calcitriol in neither the control nor calcification groups.
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Figure 3.7

SEM Images (1000x Magnification) of Day 7 Samples

SEM images of (A) control, (B) calcification, (C) 100 nM control, and (D) 100 nM
calcification after 7 days.
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Figure 3.8

SEM Images (1000x Magnification) of Day 14 Samples

SEM images of (A) control, (B) calcification, (C) 100 nM control, and (D) 100 nM
calcification after 14 days
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Figure 3.9

Percent Area of Calcium Deposits

There was no significant difference between vehicle group and 100 nM group at either
treatment or time point
The protein expression of αSMA, SM-MHC, ALP, and klotho were examined
using western blot analysis. The relative protein expression can be found in Figure 3.10.
At 7 and 14 days, there was a decrease in αSMA between the control and calcification
groups. However, there did not appear to be any effect in αSMA expression caused by the
addition of 100 nM in either the control and calcification groups. SM-MHC expression
followed a similar trend as αSMA but to a lesser degree. There also did not appear to be
any difference ALP expression between the control and calcification groups at 7 or 14
days, and there also did not appear to be any effects from the supplementation of
calcitriol. Lastly, there did not appear to be any change to the total klotho expression
between any of the groups. Total ERK was used as a loading control. Densitometric
analysis could not be done for these proteins because the three replicates were combined
to ensure that there was enough protein to load on the gels.
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Figure 3.10

Analysis of αSMA, SM-MHC, ALP, and Klotho Protein Expression

The relative expression of MMP-2 and -9 was examined using gelatin
zymography and can be seen in Figure 3.11. The presence of what is believed to be
proMMP-2 can clearly be seen in all groups at both 7 and 14 days. A much smaller band
for proMMP-9 can faintly be seen. According to densitometric analysis, as seen in figure
3.11, there was no difference proMMP-2 expression between the calcification and control
groups nor between the vehicle and 100 nM calcitriol groups.

Figure 3.11

Analysis of MMP-2/-9 Expression
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Figure 3.12

Densitometric Analysis of ProMMP-2 Expression

There was no significant difference in proMMP-2 expression between any of the groups

Effects of Calcitriol, FGF-23, and Klotho Supplementation on VSMC Calcification
In order to observe the effects from the interaction of calcitriol, FGF-23, and
klotho, various combinations of these molecules were added to VSMCs in calcifying
conditions and examined for calcium content using AA. As seen in Figure 3.13, there is a
significant decrease in calcium content from the addition of FGF-23 with calcitriol. This
combination actually reduced the calcium content to the same level as VSMCs without
calcification media. Surprisingly, the only combination to increase calcification was the
combination of calcitriol, FGF-23, and klotho, which was significantly higher than all
other groups.
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Figure 3.13

Effect of Calcitriol, FGF-23, and Klotho Supplementation on VSMC
Calcification

* P < 0.05 compared to all groups; # P < 0.05 compared to calcification group
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CHAPTER IV
DISCUSSION
In the first experiment, we wanted to determine if there was any difference in the
utilization of calcitriol between VSMCs that received 3 mM inorganic phosphate and
VSMCs that did not receive any inorganic phosphate. We saw an increase in calcitriol
concentration in the cell culture media from before administration to after 3 days of
administration on the VSMCs in both groups. Calcitriol is found in serum, but it is only
present in very small amounts (~1000x less) compared to the metabolite 25(OH)D (54).
While the majority of calcitriol activation occurs in the kidneys, various tissues can
express the CYP27B1 enzyme, including VSMCs (96). Thus, this increase in both groups
was expected. While the calcification of VSMCs is believed to involve the transition to
an osteoblast-like phenotype, osteoblasts are also capable of expressing the CYP27B1
enzyme (97); thus, it is not entirely surprising that there was not a difference in the
degree of increase in calcitriol concentration between the calcifying and non-calcifying
VSMCs. We conducted AA to ensure that our VSMCs were increasing their mineral
deposition in response to the 3 mM inorganic phosphate. Our calcifying VSMCs showed
increased calcification, consistent with previous studies (9, 11-13).
When looking at the concentration-dependent effects of calcitriol on VSMC
calcification, we saw that 100 nM and 1000 nM calcitriol supplementation was able to
increase the calcification in the presence of high phosphate and only 1000 nM calcitriol
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supplementation was able to increase the calcification without the presence of high
phosphate. These results generally agree with many previously published in vitro studies
(84, 86, 87). Jono et al were able to show that concentrations as low as 10 nM calcitriol
was able to increase calcification in the presence of high phosphate; however in this
study, they did not use charcoal stripped FBS (84), which may be the reason our 10 nM
group did not show a significant increase in calcium content. To the best of our
knowledge, we are the first group to examine concentrations as high as 1000 nM
calcitriol. Cardus et al examined 300 nM calcitriol and showed there was no difference in
calcium content compared to the 100 nM group (86), similar to our 100 and 1000 nM
groups.
When we further examined the effects of 100 nM calcitriol supplementation on
the VSMCs, we first verified our findings from the previous experiment. Interestingly, at
7 days, 100 nM calcitriol supplementation did not increase calcification in the presence of
high phosphate but did in the absence of high phosphate. After 14 days, the results were
the same as the experiment using the three calcitriol concentrations, in that 100 nM
calcitriol supplementation increased calcification in the presence of high phosphate but
did not in the absence of high phosphate after 14 days. No one has previously noted a
time dependent effect of calcitriol on VSMC calcification; however, it is worth noting
that calcitriol’s effects on osteoblast differentiation is highly dependent on the stage of
maturation of the cell (97). In fact, recent research has shown that calcitriol accelerates
matrix vesicle formation in osteoblasts but only during the early phase of differentiation
(98). Thus, it is possible that calcitriol has a similar time-dependent effect on VSMCs.
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Still, it is surprising that only the control showed increased calcification at day 7 and not
both groups.
Looking at the SEM images, there appears to mineral formation in the
calcification groups. Nodule formations appear in large number in the calcification
groups but not the control groups, suggesting that these are the mineral deposits.
Comparing the vehicle groups to the 100 nM calcitriol groups, there do not appear to be
any distinct morphological differences to suggest a cause for the increase in calcification
caused by the calcitriol supplementation. To the best of our knowledge, we are the first
group to observe calcifying VSMCs using SEM. Schembri et al observed calcification of
a carotid artery section that had atherosclerotic plaque (99), but these morphologies are
very different.
Looking at the protein expression, we saw a loss of αSMA and SM-MHC
expression in the calcification groups compared to the control groups at 7 and 14 day.
This is consistent with previous studies that show that VSMCs undergo transition to an
osteoblast-like phenotype with the addition of high phosphate (13). On the other hand,
there did not appear to be a difference in αSMA and SM-MHC expression between the
vehicle and 100 nM calcitriol groups at either 7 or 14 days. Han et al showed an increase
in runx2 expression after the supplementation of 100 nM calcitriol (87). While we were
unable to detect runx2 expression in our cells (data not shown), upregulation of runx2 is
typically coupled with the loss of smooth muscle markers, so it is surprising that we did
not see a difference in αSMA or SM-MHC. In our study, we saw that total klotho
expression was unaffected by both calcitriol and phosphate supplementation. Lim et al
actually showed an increase in transmembrane klotho with calcitriol supplementation,
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which allowed the combination of calcitriol and FGF-23 to decrease VSMC calcification
(91). We did not detect any transmembrane klotho expression, but because we also saw a
similar decrease in calcification with the combination of calcitriol and FGF-23, it is
possible that our sample preparation prevented us from detecting the transmembrane
form and only total klotho. The last protein expression we examined was for MMP-2 and
-9. As mentioned earlier, the degradation of elastin plays a large role in the pathology of
medial calcification. Rahman et al examined the MMP expression of heart tissue from
VDR knockout and wild type mice. They showed that MMP activity and expression was
higher in the knockout mice than wild type mice (100). Looking at our gelatin
zymography results, we see a large band in each group, which we believe to be proMMP2. We can also see a faint band for what appears to be proMMP-9 in each group. These
are the inactive forms of MMP-2 and -9, respectively, and the expression of these
proteins do not appear to be effected by the addition of calcitriol or phosphate. MMP-2
and -9 activity is upregulated with medial calcification; however, it has only been shown
in vivo (31-33) and in vitro when elastin peptides were added to the VSMCs (37). It is
possible that increased MMP-2 and -9 expression and activity requires the interaction
with elastin in the extracellular matrix and not just high extracellular phosphate. For this
reason, we cannot conclude that calcitriol does not have an effect on MMP expression.
Lastly, we examined the effects of combinations of 100 nM calcitriol, 10 ng/mL
FGF-23, and 0.4 nM soluble klotho. As mentioned earlier, we saw a significant decrease
in calcification with the combination of calcitriol and FGF-23, agreeing with the findings
of Lim et al. They were able to show that this decrease is due to the increased expression
of transmembrane klotho, as klotho siRNA was able to abolish this decrease in their
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study (91). It is believed that the increased expression of transmembrane klotho allows
FGF-23 to react with its receptor and exert a beneficial effect. Hu et al showed that the
addition of 0.4 nM soluble klotho by itself decreased VSMC calcification in vitro (101).
In our study, 0.4 nM soluble klotho by itself appeared to cause a small decrease in
calcification; however, statistical analysis concluded that it was not significant. In their
experiment, they only added 2 mM inorganic phosphate to the VSMCs, so it is possible
that 0.4 nM was too low of a concentration to elicit a similar, beneficial effect on the
VSMC calcification caused by 3 mM inorganic phosphate in our study. The most
surprising result was that the addition of all three, calcitriol, FGF-23, and soluble klotho,
caused an extreme increase in VSMC calcification. This is the first time this combination
has been added to VSMCs in the presence of high phosphate in vitro. Research has
shown that soluble klotho can still act as a coreceptor for FGF-23 signaling (102),
although it is believed to not be as active as the membrane form. Because the FGF-23 +
calcitriol group and the FGF-23 + klotho group do not experience an increase in
calcification, it may be possible that the combination of calcitriol, FGF-23, and klotho
causes an overexpression of klotho and allows for excess FGF-23 activity. Supporting
this idea, Jimbo et al found that FGF-23 causes concentration-dependent increase of
calcification in klotho-overexpressing VSMCs in the presence of high phosphate (103).
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CHAPTER V
FUTURE WORKS
The initial motivation for this project was to examine the feasibility of a sitespecific treatment of calcitriol to reduce vascular calcification. While there are treatments
for the plaque buildup associated with atherosclerosis and intimal calcification, such as
balloon angioplasty and stents, there are not any clinically available treatment for medial
calcification.
While our study, combined with previously published studies, do not particularly
support a calcitriol treatment for vascular calcification, they also do not rule out the
possibility for it. Future studies should be aimed at further examining the interaction
between calcitriol, FGF-23, and klotho in calcifying conditions. The mechanisms behind
the decrease or increase needs to be elucidated in order to ensure the safety of calcitriol
supplementation. In addition, because treatments are often started after symptoms appear,
the possibility of the combination of calcitriol and FGF-23 to reverse pre-existing
calcification needs to be examined.
If the research still supports the creation of a site specific treatment using
calcitriol, the delivery vehicle needs to be created. In particular, this could be done
utilizing nanoparticles, due to their ability to be functionalized with various molecules,
ability to avoid clearance by the immune system, and ability to reach the medial layer of
arteries. The nanoparticles would need to be functionalized with a targeting agent in order
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to deliver calcitriol locally and avoid the increase in serum calcium and phosphate caused
by systemic administration. In particular, modification with an antibody specific for
elastin has shown promise in targeting the sites of vascular calcification specifically by
binding to the degraded elastin that is thought to be the sites of initial mineral nucleation
(104). These nanoparticles would need to be examined for their ability to load calcitriol,
release calcitriol, and accumulate in the sites of vascular calcification.
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ADDITIONAL SEM IMAGES
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Figure A.1

SEM Images (250x) of Day 7 Samples

SEM images of (A) control, (B) calcification, (C) 100 nM control, and (D) 100 nM
calcification after 7 days
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Figure A.2

SEM Images (5000x) of Day 7 Samples

SEM images of (A) control, (B) calcification, (C) 100 nM control, and (D) 100 nM
calcification after 7 days
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Figure A.3

SEM Images (250x Magnification) of Day 14 Samples

SEM images of (A) control, (B) calcification, (C) 100 nM control, and (D) 100 nM
calcification after 14 days
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Figure A.4

SEM Images (5000x) of Day 14 Samples

SEM images of (A) control, (B) calcification, (C) 100 nM control, and (D) 100 nM
calcification after 14 days
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